MRKMerck Sharp & Dohme LLCFinished
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Colorectal Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 563 (final count)
- Started
- Mar 29, 2021
- Main results expected
- Sep 27, 2024
- Fully finished
- Sep 27, 2024
- Results posted
- Apr 9, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Global Cohort: Overall Survival (OS)
Measured over: Up to approximately 22 months (through sSAP pre-specified Final Analysis database cut-off date of 20-Feb-2023)
China Cohort: Overall Survival (OS)
Measured over: Up to approximately 35 months (through sSAP pre-specified Final Analysis database cut-off date of 27-Sep-2024)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04776148 · record last updated 2026-02-05 · checked 2026-11-09 15:47 UTC